Rheumatoid arthritis is a chronic systemic autoimmune disease characterized by a chronic inflammation of joints mediated by T-cells (a subtype of white blood cells that plays a central roll in cell-mediated immunity).
Rheumatoid arthritis affects 1% of world population. The disease starts with the inflammation of the synovial membrane, which frequently leads to the destruction of adjacent cartilage and bone. These provoke a moderate physical inability in 80% of the patients and an early death.
Evidence in recent years has suggested that the bone marrow may be involved, and may even be the initiating site of the disease. Abnormalities in hemopoietic stem cells survival, proliferation and aging have been described in patients affected by Rheumatoid arthritis and ascribed to abnormal support by the bone marrow microenvironment.
Mesenchymal stem cells and their progeny constitute important components of the bone marrow niche. Studies suggest that the onset of inflammatory arthritis is associated with altered self-renewal and differentiation of bone marrow mesenchymal stem cells, which alters the composition of the bone marrow microenvironment.
Stem cells therapy consists of the direct administration of the cells into the affected joint or in areas immediately surrounding the injury in order to regenerate damaged tissue, with the subsequent improvement of joint functionality.
With the urgent need for more effective treatments for Rheumatoid arthritis, particularly for those with more progressive forms of the disease, Stem Cells Transplant Institute believes that the potential of all types of cell therapies must be explored, and we aim to provide a secure environment and excellent professionals for your needs